UNSPSC 51312501: Arpromidine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25FN6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85713MT0EH, chemically known as guanidine, n-(3-(4-fluorophenyl)-3-(2-pyridinyl)propyl)-n-(3-(1h-imidazol-4-yl)propyl)- but generally known as arpromidine, which bears US NIH Compound Identifier 65895. European Medicines Agency schedules Arpromidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05570MIG.

UNSPSC 51312501 Arpromidine, a Commodity code, shows minimal recent activity directly aligned with the pharmaceutical ingredient itself; the posted state and local opportunities instead cluster around finished pharmaceutical products and pharmacy benefit administration rather than arpromidine as an active pharmaceutical ingredient. The code's nominal scope does not match the work actually being solicited under it in the recent record. State and local governments procuring through this code are sourcing naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and pharmacy benefit program infrastructure for direct-to-manufacturer prescription fulfillment. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances serving state and local government facilities.

The most recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, requiring electronic bid submission with shipping and delivery costs included and a two-year initial term with optional one-year renewal. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting capacity outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance posted an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification with a two-year contract term beginning July 1, 2026.